Latest filing published 23 Jul 2021 for Medicinova INC, €85k.
Based on 15 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Yuichi Iwaki (chief executive) discloses dealings in 2 companies, chiefly Avigen Inc \DE and Medicinova Inc. The record holds 65 filings, for trades running from 2 March 2006 to 9 July 2021.
In open-market terms, that means 16 purchases worth €136k on one side and 34 sales worth €477k on the other. No amount is published for 1 filing, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 3 share grants and 11 option exercises.
Half of the purchases are above €3,648 and half below. For 15 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 53% of cases, with a median move of +0.9%. These figures describe past trades and do not predict future prices.
The newest entry dates from 23 July 2021: an option exercise of €85k, in Medicinova Inc. The latest purchase dates back some time: it was published 2,417 days ago, on 12 March 2020. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 65 declarations